Outcome and incidence of appropriate implantable cardioverter-defibrillator therapy in patients with cardiac amyloidosis
详细信息 查看全文
- 作者：David Hamona ; 1 ; 2 ; david.a.hamon@gmail.com" class="auth_mail" title="E-mail the corresponding author ; Vincent Algalarrondob ; 1 ; Estelle Gandjbakhchc ; Fabrice Extramianad ; Eloi Marijone ; Nathalie Elbaza ; Dounia Selhaneb ; Jean-Luc Dubois-Randea ; Emmanuel Teigera ; Violaine Plante-Bordeneuvef ; g ; Thibaud Damya ; g ; Nicolas Lellouchea ; g
- 关键词：Cardiac amyloidosis ; Implantable cardioverter defibrillator ; Ventricular arrhythmia ; Sudden cardiac death ; Hereditary transthyretin
- 刊名：International Journal of Cardiology
- 出版年：2016
- 出版时间：1 November 2016
- 年：2016
- 卷：222
- 期：Complete
- 页码：562-568
- 全文大小：523 K
文摘
- •
Appropriate ICD therapies in CA patients are common (27% of the patients), regardless of CA and prevention types
- •
Conventional selection criteria for ICD implantation in primary prevention (e.g. LVEF) are not suitable for CA patients.
- •
Patients with an advanced form of CA, particularly the AL-CA type, had a very poor outcome despite ICD placement.
- •
TTR-CA with early cardiac involvement and AL-CA awaiting cardiac transplant should be patients considered for an ICD.
- •
Prospective studies are warranted to further investigate whether prophylactic ICD implantation would reduce mortality in CA.